Trovagene,Inc. (NASDAQ:TROV) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September14, 2017, Trovagene,Inc. (the “Company”) appointed Athena Countouriotis, M.D. as a director of the Company, effective immediately. Dr.Countouriotis does not have any family relationship with any director, executive officer or person nominated or chosen by us to become a director or executive officer. There is no understanding or arrangement between Dr.Countouriotis and any other person to which Dr.Countouriotis was selected as a director. There are no transactions in which Dr.Countouriotis has an interest requiring disclosure under Item 404(a)of Regulation S-K. In connection with her appointment, Dr.Countouriotis received an option to purchase 38,106 shares of the Company’s common stock exercisable at $0.72 per share, the closing price of the Company’s common stock on the Nasdaq Capital Market on September13, 2016. The options vest over three (3)years in 3 annual installments beginning on the one year anniversary of the date of issuance.
A copy of the press release announcing the appointment of Dr.Countouriotis is attached as Exhibit99.1 to this Form8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d)Exhibits.
99.1 Press Release of Trovagene,Inc. dated September20, 2017
Trovagene, Inc. ExhibitEX-99.1 2 a17-22257_1ex99d1.htm EX-99.1 Exhibit 99.1 Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis Dr. Athena Countouriotis joins Trovagene’s Board of Directors,…To view the full exhibit click here
About Trovagene,Inc. (NASDAQ:TROV)
Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.
